克罗诺斯集团因交易量激增而飙升

Cronos Group Inc.（纳斯达克股票代码：CRON）周二交易量异常强劲，共有 4,756,022 股易手，较前一交易日交易量激增 91%。该股收盘价为 2.67 美元，高于之前的收盘价 2.49 美元。

Cronos Group Shares Soar Amid Surge in Trading Volume

克罗诺斯集团股价因交易量激增而飙升

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the cannabinoid industry, witnessed a notable surge in trading activity on Tuesday. The company's stock volume reached approximately 4,756,022 shares, representing a significant 91% increase from the previous session's volume of 2,487,493 shares. The stock closed the day at $2.67, up from its previous close of $2.49.

大麻素行业的知名企业克罗诺斯集团公司（纳斯达克股票代码：CRON）周二的交易活动显着激增。公司股票成交量达到约4,756,022股，较上一交易日的2,487,493股大幅增加91%。该股当日收盘价为 2.67 美元，高于前一收盘价 2.49 美元。

Analyst Coverage

分析师报道

Bank of America recently upgraded its price target on Cronos Group shares, raising it from $1.78 to $2.00. However, the firm maintained an "underperform" rating for the company in a research note dated December 28th, 2023.

美国银行最近上调了 Cronos Group 股票的目标股价，从 1.78 美元上调至 2.00 美元。然而，该公司在 2023 年 12 月 28 日的研究报告中维持该公司“表现不佳”的评级。

Stock Performance and Valuation

股票表现和估值

Cronos Group shares have gained 6.0% year-to-date. The company currently has a market capitalization of $1.01 billion, a P/E ratio of -13.89, and a beta of 1.13. Its 50-day moving average price stands at $2.14, while its 200-day moving average price is $2.05.

Cronos Group 股价今年迄今已上涨 6.0%。该公司目前市值为10.1亿美元，市盈率为-13.89，贝塔值为1.13。其50天移动平均价格为2.14美元，200天移动平均价格为2.05美元。

Financial Results

财务业绩

Cronos Group last reported its quarterly financial results on February 29th, 2023. The company posted a loss of $0.05 per share for the quarter. Revenue for the period amounted to $23.92 million, falling short of the consensus estimate of $25.15 million. Cronos Group's return on equity and net margin were negative, at -3.99% and -84.15%, respectively.

Cronos Group 上次于 2023 年 2 月 29 日公布了季度财务业绩。该公司公布该季度每股亏损 0.05 美元。该期间收入为 2,392 万美元，低于市场普遍预期的 2,515 万美元。 Cronos Group的股本回报率和净利润率为负，分别为-3.99%和-84.15%。

Earnings Outlook

盈利展望

Analysts anticipate that Cronos Group Inc. will report a loss of $0.01 per share for the current fiscal year.

分析师预计 Cronos Group Inc. 本财年每股亏损 0.01 美元。

Institutional Ownership

机构所有权

Hedge funds and other institutional investors have recently adjusted their positions in Cronos Group. Chesapeake Capital Corp IL established a $25,000 stake in the company during the fourth quarter, while Cetera Investment Advisers acquired a $38,000 stake in the same period. Deutsche Bank AG significantly increased its holdings by 21,218.6%, purchasing 14,853 additional shares during the fourth quarter. Quantbot Technologies LP and Cetera Advisor Networks LLC initiated new positions in Cronos Group in the second and second quarters, respectively. Institutional investors collectively own 8.63% of the company's outstanding shares.

对冲基金和其他机构投资者最近调整了在克罗诺斯集团的仓位。 Chesapeake Capital Corp IL 在第四季度购买了该公司 25,000 美元的股份，而 Cetera Investment Advisers 同期收购了 38,000 美元的股份。德意志银行在第四季度大幅增持股份 21,218.6%，额外购买了 14,853 股。 Quantbot Technologies LP 和 Cetera Advisor Networks LLC 分别于第二季度和第二季度在 Cronos Group 中设立了新职位。机构投资者合计持有该公司已发行股份的8.63%。

Company Profile

公司简介

Cronos Group Inc. is engaged in the production and distribution of cannabinoid products. The company operates in the United States, cultivating, manufacturing, and marketing cannabis and cannabis-derived products for medical and adult-use markets. Additionally, it manufactures, markets, and distributes hemp-derived supplements and cosmetic products under the Lord Jones brand through various distribution channels.

Cronos Group Inc. 从事大麻素产品的生产和分销。该公司在美国运营，为医疗和成人使用市场种植、制造和营销大麻及大麻衍生产品。此外，它还通过各种分销渠道以 Lord Jones 品牌制造、营销和分销大麻衍生补充剂和化妆品。

Recommendations

建议

MarketBeat, a platform that tracks top-rated research analysts and their stock recommendations, has identified five companies that analysts are bullish on. Notably, Cronos Group is not included in this list of recommended stocks.

MarketBeat 是一个跟踪顶级研究分析师及其股票推荐的平台，它已经确定了分析师看好的五家公司。值得注意的是，克罗诺斯集团并未包含在此推荐股票名单中。

Disclaimer

免责声明

This article is for informational purposes only and should not be considered investment advice. Investors should conduct due diligence and consult with a financial professional before making any investment decisions.

本文仅供参考，不应被视为投资建议。投资者在做出任何投资决定之前应进行尽职调查并咨询金融专业人士。